The ΔGbinding of Apelin with GLP-1R (−96.70 kcal/mol) and IL-6R (−163.66 kcal/mol) also indicates its potential to mitigate inflammation and improve glucose metabolism, further reinforcing its utility in addressing comorbidities often associated with CAD. Here, APLN is linked to coronary artery disorder.